Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Phase 1 SDC-1801 vs Brepocitinib which JR spoke about here: https://youtu.be/1x1_ktQPLik?feature=shared&t=3470
Brepocitinib has been making some waves lately and recently pulled good results in Lupus our pre clin data looks really good for 1801/1802, same with TLL-018 In RA head to head with Tofa which we have some good early data where SDC-1801 (SAR20347) absolutely smashed Tofa.
Articles below covering Brepocitinib PK data:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015086/
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.15786
----------------------------------
The Alpine acquisition bolsters Vertex’s standing in the immunology space as other pharmas look to stand out. Johnson & Johnson CEO Joaquin Duato told investors in February that he sees opportunity for additional M&A in areas like neuroscience and immunology, and Takeda completed its $4 billion purchase of Nimubs’ TYK2 candidate back in February 2023. Other pharmas, like AbbVie, Bristol Myers Squibb and Sanofi, have doubled down on investing in immunology.
https://www.fiercebiotech.com/biotech/vertex-pays-49-billion-hike-alpines-immunology-trail
-----------------------------------
Not forgetting that our CHK1 was on-licensed 4 months into its P1 so a license deal for SDC-1801 can fall anytime and not just on results. If the Bod now have sight of a potential funding partner for P2a ref Edison then that will in turn strengthen any licence negotiations for larger sums....
To say money is tight I still can't get my head around why they want to chuck the money at pre-clinical / Pot anyone pre-clinical projects could that be to resolve previous issues on 1801 so to get approval for a P2a in the UK in the future? Or am I barking Mad
The WRAP raised 1.12m when they only required 300k the difference what we owe RF so they have the additional 800k sat in the bank and so far have chosen not to clear RF instead they are going to spend it on pre-clinical projects and potentially further pre-clinical studies on SDC-1802
In fact why are they even talking about spending the extra money on preclinical hasn't every RNS stated that all funds are being directed at 1801, it's like they don't even know what to do with it, how about pay off RF you Muppets or keep it towards P2a or for extended working capital..
Answers?
By the removal of paying RF in "cash" from the RNS and now stating "the Company expects to settle all balances by the issuance of Subscription Shares prior to the Maturity Date" That feels like a kick in the nuts after the extra WRAP raised and to do what crack on with 1802 when they never should of stopped working on it... frustrating as f**k this share.
Let's hope we get a positive RNS soon....GLA
Looks like RF get can request new shares as soon as they run out I was really hoping either Sar would clear the outstanding with additional WRAP raised or there was some timeframe breathing space between issuing shares but seems not....
Thoughts why cash has has been removed from todays RNS?
Today’s RNS: The Company expects to settle all balances by the issuance of Subscription Shares prior to the Maturity Date. No further drawdown are expected to be made under the Facility.
March 28th RNS: The Company expects to settle all balances by the issuance of shares or cash payment prior to the Maturity Date. No further drawdown are expected to be made under the Facility.
Agreed Aber definitely need a standalone MAD Preliminary results RNS with all the bells & whistles it’s taken enough years to get here, a general trading update needs to be a separate RNS with any mention of RF etc /MAD Pre Results due any day now let’s see how high we can set the bar…
Absolute crazy how much some of the US Bio start ups can raise compared to the UK and just how undervalued we are just look at Avenzo raised $350m in a year to license in assets: https://avenzotx.com/news/
https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-24